Recent Press Releases

NIH scientists map first steps in flu antibody development

NIH scientists map first steps in flu antibody development Knowing origin of broadly neutralizing antibodies could aid universal flu vaccine design National Institutes of Health scientists have...

Pascal Soriot appointed Chief Executive Officer of AstraZeneca

Pascal Soriot appointed Chief Executive Officer of AstraZeneca Tuesday, 28 August 2012 AstraZeneca today announced that Pascal Soriot has been appointed as the company's Chief Executive Officer....

Compound discovered that boosts effect of vaccines against HIV and flu

Compound discovered that boosts effect of vaccines against HIV and flu Novel vaccine additive to enhance the body's immune response shows promise in mice Oxford University scientists have...

PATH Malaria Vaccine Initiative (MVI) Creates New Central "Reference" Lab, Standardizing Ability to Measure Performance of Malaria Vaccine Formulations

PATH Malaria Vaccine Initiative (MVI) Creates New Central "Reference" Lab, Standardizing Ability to Measure Performance of Malaria Vaccine Formulations MVI, International AIDS Vaccine...

NIH Awards $7.8 Million for Innovative HIV Vaccine Approaches

NIH Awards $7.8 Million for Innovative HIV Vaccine Approaches Fourteen Grantees to Focus on Basic Vaccine Discovery Research The National Institute of Allergy and Infectious Diseases (NIAID), part of...

PATH Malaria Vaccine Initiative (MVI) Creates New Central "Reference" Lab, Standardizing Ability to Measure Performance of Malaria Vaccine Formulations

MVI, International AIDS Vaccine Initiative, and Imperial College London Establish Collaboration to Guide Selection and Prioritization of Malaria Vaccine Candidates WASHINGTON, Aug. 20, 2012...

Genocea Initiates a Phase 1/2a Study with Its Therapeutic Vaccine Candidate for Herpes Simplex Virus-2 (HSV-2)

Genocea Initiates a Phase 1/2a Study with Its Therapeutic Vaccine Candidate for Herpes Simplex Virus-2 (HSV-2) CAMBRIDGE, Mass--Genocea Biosciences announced today that it has initiated a Phase 1/2a...

IDRI and Medicago Announce FDA Authorization to Initiate a Phase 1 Clinical Trial for an H5N1 Vaccine with GLA Adjuvant

IDRI and Medicago Announce FDA Authorization to Initiate a Phase 1 Clinical Trial for an H5N1 Vaccine with GLA Adjuvant SEATTLE and QUEBEC CITY, Aug. 16, 2012 -- The Infectious Disease Research...

A Vaccine for Heart Disease? La Jolla Institute Discovery Points Up This Possibility

A Vaccine for Heart Disease? La Jolla Institute Discovery Points Up This Possibility Researcher finds autoimmune response contributes to inflammation in the artery wall SAN DIEGO - (August 13, 2012)...

PATH Malaria Vaccine Initiative Names Eminent Malaria Scientists and Vaccinologists to Advisory Council

PATH Malaria Vaccine Initiative Names Eminent Malaria Scientists and Vaccinologists to Advisory Council WASHINGTON, Aug. 13, 2012 -- The PATH Malaria Vaccine Initiative (MVI) recently named some of...

PATH Malaria Vaccine Initiative Names Eminent Malaria Scientists and Vaccinologists to Advisory Council

WASHINGTON, Aug. 13, 2012 /PRNewswire-USNewswire/ -- The PATH Malaria Vaccine Initiative (MVI) recently named some of the world's most eminent malaria scientists and vaccinologists to its...

FDA approves vaccines for the 2012-2013 influenza season

FDA approves vaccines for the 2012-2013 influenza season The U.S. Food and Drug Administration announced today that it has approved the 2012-2013 influenza (flu) vaccine formulation for all six...

PharmAthene Receives FDA Notification On SparVax™

PharmAthene Receives FDA Notification On SparVax™ ANNAPOLIS, Md., Aug. 10, 2012 -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against...

Positive Clinical Trial Results for Immunovaccine's DPX-0907 Published in Journal of Translational Medicine

Positive Clinical Trial Results for Immunovaccine's DPX-0907 Published in Journal of Translational Medicine Novel Cancer Immunotherapy Generates Polyfunctional T Cell Responses in Multiple Tumor...

immatics announces publication of IMA901 cancer vaccine data in Nature Medicine: immune response associates with longer survival

immatics announces publication of IMA901 cancer vaccine data in Nature Medicine: immune response associates with longer survival Paper highlights clinical and immunological activity of IMA901 in...

FDA Clinical Hold Lifted - Phase III Study Agreed

FDA Clinical Hold Lifted - Phase III Study Agreed Allergy Therapeutics plc, (AIM: Allergy or the "Company"), the specialist pharmaceutical company focused on allergy vaccination, today announces that...

GlaxoSmithKline shipping U.S. flu vaccine with new strain coverage recommended for 2012-2013

GlaxoSmithKline shipping U.S. flu vaccine with new strain coverage recommended for 2012-2013 PHILADELPHIA, July 31, 2012 -- /PRNewswire/ -- GlaxoSmithKline [NYSE: GSK] announced today it has begun...

Novartis begins shipment of Fluvirin® seasonal influenza vaccine in US for 2012-2013 influenza season

Novartis begins shipment of Fluvirin® seasonal influenza vaccine in US for 2012-2013 influenza season -- Novartis plans to ship more than 30 million doses of Fluvirin vaccine to US customers for...

IAVI Welcomes New Members to Board of Directors

IAVI Welcomes New Members to Board of Directors IAVILauren Wesolowski212-328-7420 The International AIDS Vaccine Initiative (IAVI) today announced the appointment to its Board of Directors of Alice...

Alnylam Earns Milestone Payment from GlaxoSmithKline in VaxiRNA Collaboration on Flu Vaccine Production

Alnylam Earns Milestone Payment from GlaxoSmithKline in VaxiRNA Collaboration on Flu Vaccine Production CAMBRIDGE, Mass., Jul 30, 2012 -- Alnylam Pharmaceuticals, Inc. ALNY -4.50% , a leading RNAi...